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Abstract
Background: Pharmacological inhibition of B cell receptor (BCR) signaling has recently emerged as an effective
approach in a wide range of B lymphoid neoplasms. However, despite promising clinical activity of the first Bruton’s
kinase (Btk) and spleen tyrosine kinase (Syk) inhibitors, a small fraction of patients tend to develop progressive
disease after initial response to these agents.
Methods: We evaluated the antitumor activity of IQS019, a new BCR kinase inhibitor with increased affinity for Btk,
Syk, and Lck/Yes novel tyrosine kinase (Lyn), in a set of 34 B lymphoid cell lines and primary cultures, including
samples with acquired resistance to the first-in-class Btk inhibitor ibrutinib. Safety and efficacy of the compound
were then evaluated in two xenograft mouse models of B cell lymphoma.
Results: IQS019 simultaneously engaged a rapid and dose-dependent de-phosphorylation of both constitutive and
IgM-activated Syk, Lyn, and Btk, leading to impaired cell proliferation, reduced CXCL12-dependent cell migration,
and induction of caspase-dependent apoptosis. Accordingly, B cell lymphoma-bearing mice receiving IQS019
presented a reduced tumor outgrowth characterized by a decreased mitotic index and a lower infiltration of
malignant cells in the spleen, in tight correlation with downregulation of phospho-Syk, phospho-Lyn, and
phospho-Btk. More interestingly, IQS019 showed improved efficacy in vitro and in vivo when compared to the
first-in-class Btk inhibitor ibrutinib, and was active in cells with acquired resistance to this latest.
Conclusions: These results define IQS019 as a potential drug candidate for a variety of B lymphoid neoplasms,
including cases with acquired resistance to current BCR-targeting therapies.
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Background
The B cell receptor (BCR) regulates multiple cellular
processes which are critical for maintenance and survival
of B cells, including proliferation, differentiation, and cell
migration [1]. Antigen engagement to BCR extracellular
domain leads to phosphorylation and activation of
immunoreceptor tyrosine-based activation motifs located
in the cytoplasmic portion and other proteins downstream
the receptor. Within BCR signalosome, the Lck/Yes novel
tyrosine kinase (Lyn) recruits and phosphorylates the
spleen tyrosine kinase (Syk), triggering a proliferation and
survival cascade signaling that involves the phosphoryl-
ation and activation of Brutons’ tyrosine kinase (Btk),
which subsequently phosphorylates phospholipase Cγ2
(PLCγ2), leading to calcium mobilization and activation of
several downstream pathways, including MAP kinases,
Akt and NF-κB [2]. In addition to tonic, ligand-mediated
BCR signaling, chronic BCR activation can occur in the
absence of antigen engagement [3], leading to aberrant,
constitutive BCR activation in several B cell non-Hodgkin
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lymphoma (B-NHL) subtypes, including diffuse large B-
cell lymphoma (DLBCL), mantle cell lymphoma (MCL),
follicular lymphoma (FL), and chronic lymphocytic
leukemia (CLL) [4–7]. In these entities, BCR signaling
represents an important pro-survival stimulus that may
be stronger than in normal B cells, supporting the recent
emergence of several BCR-targeting therapies [7]. But
despite the promising results obtained with the first
kinase inhibitors, such as fostamatinib and ibrutinib,
specific for the Src-family kinases Syk and Btk [8], the
design of new compounds is warranted to improve treat-
ment efficacy and to by-pass the resistance appearing in
primarily responsive patients [9–11]. In this context, we
recently described the synthesis of a new family of 4-
aminopyrido[2,3-d]pyrimidines with kinase inhibitory
property and antitumoral activity in B lymphoid cells.
Compound 19 (thereafter referred as IQS019) was iden-
tified as the most effective and specific molecule, with
growth inhibitory 50 (GI50) doses in the low micromolar
range. Docking studies and biochemical assays further
showed that the compound inhibited the active site of
the BCR kinases Syk, Lyn, and Btk with higher efficacy
than the reference kinase inhibitors [12, 13]. Here, using
an extended panel of B-NHL cell lines and primary
samples, we describe the full mechanism of action of
this compound and report its remarkable antitumoral
activity in vitro and in distinct B-NHL xenotransplant
mouse models.
Methods
Cell lines and patients samples
Twenty-one cell lines from the different subtypes of B
lymphoid neoplasm were used in this study (Table 1 and
Additional file 1 Methods). All cell lines were routinely
culture at 37 °C in a humidified atmosphere with 5% car-
bon dioxide in RPMI-1640, DMEM, or IMDM culture
medium supplemented with 10–20% heat-inactivated
fetal bovine serum (FBS), 2 mM glutamine, and 50 μg/
ml penicillin-streptomycin (Thermo Fisher Scientific,
Waltham, MA, USA). Primary tumor cells from 13 CLL
patients (Additional file 1: Table S2) were used. Tumor
cells were isolated, cryopreserved, and conserved within
the Hematopathology collection of our institution
(Hospital Clínic-IDIBAPS Biobank R121001-094), as
previously described [14].
Table 1 Sensitivity of B lymphoid cell lines to IQS019




IQS019 cytotoxic effect (referred to untreated cells)
1 μM, 48 h 5 μM, 48 h
DOHH-2 FL wt 26% 100%
WSU-NHL FL del/mut 6% 80%
WSU-FSCCL FL wt 26% 77%
SC-1 FL del/mut 4% 43%
JEKO-1 MCL del/mut 21% 75%
MAVER-1 MCL del/mut 15% 70%
UPN-1 MCL del/mut 14% 66%
HBL-2 MCL del/mut 12% 64%
MINO MCL del/mut 19% 64%
GRANTA-519 MCL wt 26% 63%
Z-138 MCL wt 18% 62%
JVM-2 MCL wt 16% 58%
REC-1 MCL wt 12% 48%
MEC-2 CLL del/mut 12% 51%
JVM-13 CLL wt 7% 46%
MEC-1 CLL wt 9% 33%
SUDHL-16 GCB-DLBCL del/mut 15% 47%
OCI-LY8 GCB-DLBCL del/mut 2% 29%
SUDHL-8 GCB-DLBCL del/mut 15% 32%
OCI-LY10 ABC-DLBCL wt 3% 47%
U-2932 ABC-DLBCL del/mut 15% 51%
a17p13 deletion was assessed by fluorescence in situ hybridization and TP53 mutational status was analyzed by direct sequencing
Abbreviations: FL follicular lymphoma MCL mantle cell lymphoma, CLL chronic lymphocytic leukemia, DLBCL diffuse large B cell lymphoma
Balsas et al. Journal of Hematology & Oncology  (2017) 10:80 Page 2 of 14
Kinase inhibition profiling
The kinase inhibition profile of IQS019 (0.1 and 10 μM)
was evaluated at Proqinase (Freiburg, Germany) using a
Kinase 400-Profiler Panel, according to previously de-
scribed procedures [13]. The residual activity (in %) for
each compound well was calculated by using the following
formula: Residual activity (%) = 100 x [(signal of com-
pound–low control)/(high control–low control)].
Cell-based tyrosine kinase assay
In vitro inhibitory activity of IQS019 against BCR-related
kinase was determined by Advanced Cell Dynamics (San
Diego, CA, USA). Briefly, the Ba/F3 murine B lymphoid
cell line was transfected with either a control vector or a
vector containing the kinase domain of Btk, Syk, or Lyn,
rending each cell line dependent upon activity of the re-
combinant kinase for survival. Cells were treated for 48 h
with the indicated doses of IQS019 and cell viability was
monitored via ATP concentration using CellTiter-Glo
assay (Promega, Madison, WI, USA). IC50 values were
determined using the GraphPad Prism software version
5.04 (San Diego, CA, USA)
Cell proliferation assay
Cells (4–6 x 105 cells/ml) were treated for the indicated
times with IQS019 or ibrutinib (Selleck Chemicals,
Munich, Germany) at doses ranging from 0.1 to 20 μM,
and cell proliferation was determined by a modification
of the MTT (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltet-
razolium bromide) reduction method.
BCR stimulation and phospho-kinase detection
Cell lines (3–5 x 106 cells) and primary CLL samples (8–
10 x 106 cells) were pretreated with 1 or 2.5 μM IQS019
for 90 min in FBS-free RPMI medium. Once starved,
cells were incubated at 37 °C with 10 μg/ml of either
anti-IgM (UPN-1, JVM-13, OCI-LY10 and primary CLL
cells) or anti-IgG (DOHH-2) antibodies (Jackson Immu-
noresearch Laboratories, West Grove, PA, USA). Based on
preliminary experiments showing a cell type-dependent
variation in the optimal duration of the stimulation, cells
were exposed to their respective anti-Ig for 2 min (UPN-1
and OCI-LY10 cells), 30 min (DOHH-2 and JVM-13 cells),
and 15 min (CLL primary cells). Detection of phospho-
Syk, phospho-lyn and phospho-Btk was carried out by
western blot and flow cytometry, respectively, as detailed
in Additional file 1 Methods.
CXCL12-mediated chemotaxis
Cell lines and CLL primary cells were exposed as indicated
to IQS019, with or without BCR ligation, and CXCL12-
induced migration was evaluated using 24-well chemo-
taxis chambers containing 8 μm (cell lines) or 5 μm
(primary cells) pore size inserts (Corning Life Science,
Tewksbury, MA, USA), as previously described [15]. To
quantify CXCR4-dependent F-actin polymerization,
cells (300.000–500.000) treated as above were fixed on
poly-L-lysine–coated glass coverslips with 4% parafor-
maldehyde, washed in PBS, permeabilized for 10 min
with a solution containing 0.1% saponin (in PBS), followed
by a 30 min incubation with 50 μg/ml phalloidin-TRITC
(Sigma-Aldrich). Then, coverslips were washed three
times with saponin 0.03%, mounted on glass slides with
DAPI-containing Fluoroshield mounting medium (Sigma-
Aldrich), and visualized on a Nikon H5505 microscope by
means of a 60X NA oil objective (Nikon, Amsterdam,
Netherlands) with the use of Isis Imaging System v5.3
software (MetaSystems GmbH, Heidelberg, Germany).
Xenograft mouse models and immunohistochemical studies
For MCL xenotransplant model, CB17-SCID female
mice (Janvier Labs, Le Genest-Saint-Isle, France) were
inoculated subcutaneously with UPN-1 cells as previ-
ously described [14].Tumor-bearing mice were randomly
assigned into equivalent cohorts and received a daily
dose of 2 mg/kg, 10 mg/kg (i.p.), or 25 mg/kg (p.o.)
IQS019-2MeSO3H or ibrutinib, or equal volume of ve-
hicle, for 15 days, in a five/two (on/off) schedule. Animals
were sacrificed and tumor samples were processed and
stained for phospho-Histone H3 and cleaved caspase-3 as
previously described [14]. Detection of phospho-Syk,
phospho-Lyn and phospho-Btk was carried out from
OCT tumor section as explained in Additional file 1
Methods. For systemic FL model, 12 SCID mice were
intravenously inoculated via tail vein with 1.5 x 107
DOHH-2 cells per mouse. One week later, animals were
randomly assigned into two equivalent cohorts and
treated intraperitoneally with 2 mg/kg IQS019-2MeSO3H
or vehicle, as before. Mice were then sacrificed and immu-
nodetection of phospho-BCR kinases was performed as
detailed in Additional file 1 Methods.
Statistical analysis
Unless otherwise specified, the data are depicted as the
mean ± SD of three independent experiments. Unpaired
and paired T-tests were used to obtain the statistical
analysis using Graph Pad Prism software 4.0. Results
were considered statistically significant when p < 0.05
(*, **p < 0.01, ***p < 0.001).
Results
Antitumor effect of the 4-aminopyrido[2,3-d]pyrimidine
IQS019 in B lymphoid cell lines and primary samples
To assess the selectivity of the kinase inhibitor IQS019
(Fig. 1a and ref [13]), we first evaluated its inhibitory
property against a panel of 400 kinases, including 70
disease-relevant protein kinase mutants and 13 lipid
kinases, covering about 60% of the human kinome. We
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found the compound to be preferentially active against
tyrosine kinase (TK) and tyrosine kinase-like (TKL)
families, reaching a mean residual kinase activity of 28%
at a 10 μM dose, while this activity remained above 70%
in all the other kinase subgroups (Fig. 1b, *** p < 0.001
and Additional file 1: Figure S1). Of special interest, in a
set of 17 TK/TKLs, the compound was able to inhibit at
least 20% of the kinase activity at the lowest dose
(0.1 μM) and to achieve an almost complete kinase in-
activation at the 10 μM concentration. These kinases
corresponded to leucocyte-, BCR-, or T-cell receptor
(TCR)-related kinases (Lyn, Blk, Lck, Src, Frk, Csk, Hck,
Fyn, Btk, Syk), the member of the Tec family of non-
receptor tyrosine kinases, Bmx, and other receptor
tyrosine kinases with lower relevance in B-NHL, such as
Ddr2, Egfr, EphA, Erbb, Fgr and Braf (Additional file 1:
Table S1). Among these potential targets, a radiometric
kinase activity study further showed that IQS019 had an
IC50 in the low micromolar range for the BCR kinases
Lyn (0.15 μM), Syk (1.6 μM) and Btk (2.1 μM), corre-
sponding to those kinases able to bind the compound in
their active site [13]. Accordingly, ectopic expression of
each individual kinase in B lymphoid cells rendered
them dependent of these kinases for their survival and
increased cell sensitivity to IQS019. Indeed, while the
calculated IC50 of the compound was 5.4 μM in parental
Ba/F3 cells, this value decreased to 2.2, 1.4, and 2.2 μM
in Btk-, Lyn-, or Syk-overexpressing cells, respectively
Fig. 1 IQS019 simultaneously targets Syk, Lyn and Btk tyrosine kinases and blocks cell proliferation in distinct subtypes of B lymphoid neoplasms.
a Chemical structure of IQS019. b Selectivity kinase inhibition profile of IQS019 against tyrosine kinase (TK) and tyrosine kinase-like (TKL), when
compared to the other subfamilies of protein kinases (*** p < 0.001). c Effect of IQS019 on the proliferation of control (parental), Syk-, Lyn-, and
Btk-overexpressing Ba/F3 cells. The different cell lines were treated with increasing dose of IQS019 and proliferation blockade was assessed by
MTT assay, using untreated cells as a reference. Measured data represent the activities of duplicate determinations. d Effect of IQS019 on the
proliferation of CLL primary cultures. Cells (2 x 105) were incubated with increasing concentrations of IQS019 for 24 hours and cell viability
was determined by the MTT reduction assay. Results are the mean values ± SD of four replicates, and are referred to control, untreated cells
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(Fig. 1c). Thus, these results confirm that IQS019 is a
potent tyrosine kinase inhibitor, with the unique ability to
bind and to simultaneously inhibit the three BCR kinases
Lyn, Syk, and Btk.
We further assessed the activity of the compound in
vitro using a panel of 21 B-NHL cell lines representative
of the CLL, MCL, FL and DLBCL subtypes (Table 1).
We show that a 5 μM dose of the compound decreased
cell proliferation in all the cell lines (range: 29–100%),
being MCL and FL cells significantly more sensitive to
the compound (mean cytotoxicity at 48 h: 67.2 ± 15%)
than CLL cells and DLBCL cells of either activated B-
cell (ABC) or germinal centre B-cell (GCB) subtype
(mean cytotoxicity at 48 h: 42 ± 9%) (p = 0.0002). Based
on these results, a set of 13 CLL primary cultures were
exposed for 24 h to increasing doses of IQS019 and cell
viability was measured by MTT assay. Although a high
variability was observed among cases, the viability de-
creased in a dose-dependent manner in all the samples
treated with the compound (Fig. 1d). The calculated
IC50 was 6.1 μM in this set of samples, corresponding to
the upper range of the values found in the cell lines.
Similar responses were observed in FL and MCL pri-
mary cultures (data not shown). Of note, no association
could be established between sensitivity to IQS019 and
common cytogenetic alterations, TP53 mutation and/or
deletion, or IGHV mutational status (Table 1, Additional
file 1: Table S2 and Figure S2a). Of interest, a 24 h treat-
ment with a 5 μM dose of the compound induced about
35% apoptosis increase in the representative cell lines
UPN-1 and DOHH-2 (Additional file 1: Figure S2b). In
CLL and primary cultures (n = 6) the average cell death
induction reached 26% (range: 9.5–51.5%), as shown in
the representative cases, CLL n.2 and CLL n.10 (Add-
itional file 1: Figure S2b and data not shown). This
phenomenon was completely abrogated in the presence
of the pan-caspase inhibitor Q-VD-OPh. In parallel, the
analysis of phospho-histone H3 levels as a surrogate of
mitotic progression indicated a notable decrease of this
marker in five out of six primary CLL cases treated with
the compound (Additional file 1: Figure S2c). Thus,
altogether these results demonstrate that IQS019 antitu-
mor activity in B lymphoid cells involved both a blockade
in cell proliferation and the induction of a caspase-
dependent cell death.
IQS019 antagonizes constitutive and antigen-mediated
BCR signaling
Based on the above results, we analyzed the effect of
IQS019 on the phosphorylation status of Syk, Lyn and
Btk in four cell lines representative of MCL (UPN-1), FL
(DOHH-2), CLL (JVM-13), and DLBCL (OCI-LY10)
subtypes. Cells were incubated for 6 h with increasing
concentrations of IQS019 and phosphorylation levels of
Syk and Lyn at their respective Tyr352 and Tyr396
residues, were evaluated by Western blot, while Btk
phosphorylation at Tyr223 residue was analyzed by flow
cytometry. As observed in Fig. 2a, IQS019 treatment led
to a dose-dependent dephosphorylation of Syk and Lyn
in the four cell lines tested. Consistent with the cyto-
toxicity of the compound (Table 1), a complete dephos-
phorylation of the two kinases was observed in UPN-1
and DOHH-2, while a slight, persistent phosphorylation
of both Syk and Lyn was detected in OCI-LY10 and
JVM-13 cells (Fig. 2a). Regarding Btk phosphorylation,
flow cytometry analysis showed a 30% (UPN-1 and
OCI-LY10) and a 60% (DOHH-2 and JVM-13) decrease
in the relative mean fluorescence intensity ratio (r) of
phospho-Btk signal in cells exposed to a 5 μM dose of
the compound (Fig. 2b).
In a second step, the four previous cell lines and two
representative primary CLL cases were BCR-stimulated
with their corresponding anti-Ig in the presence of in-
creasing concentrations of IQS019, and phospho-Syk,
phospho-Lyn and phospho-Btk levels were analyzed as
above. As shown in Fig. 3a, BCR ligation induced an in-
crease in the phosphorylation levels of Syk and Lyn in
all the samples tested, that was hampered by IQS019 in
a dose-dependent manner. Remarkably, a dose of IQS019
as low as 1 μM was sufficient to completely counteract
the anti-IgM-mediated activation of Syk and Lyn in the
highly IgM-responsive (unmutated IGHV) CLL sample
showing the greatest efficacy of the stimulation (CLL#10,
Fig. 3a). Similarly, IQS019 efficiently counteracted Ig-
induced Btk phosphorylation in cell lines, as shown by a
30 to 70% reduction in relative phospho-Btk levels
(Fig. 3b). In CLL primary cells, for all but 1 cases out of
the 6 examined, IQS019 achieved a 30% reduction in
phospho-Btk levels (p = 0.0005), as shown in the represen-
tative CLL no.10 (Fig. 3b and data not shown). Of note, in
the representative cell line UPN-1, Syk-dependent phos-
phorylation of Btk at Tyr551 was negligible upon BCR
triggering and remained unaffected in the presence of
IQS019 (data not shown), suggesting that IQS019-
mediated inhibition of Btk requires a direct interaction
of the compound with the kinase, rather than an indirect,
Syk-mediated signal transduction. Altogether, these results
suggest than IQS019 counteracts both constitutive and
antigen-induced BCR signaling in B lymphoid cell lines
and primary cells.
IQS019 inhibits CXCL12-mediated migration of malignant
B cells
Migration of neoplastic B cells has been shown to be
heavily affected upon exposure to drugs targeting the
BCR-associated kinases, as these latest tightly regulate
the re-organization of the cytoskeleton required for cell
chemotaxis [15]. Thus, we evaluated the effect of
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IQS019 on the migratory capacity of malignant B cells,
using a CXCL12-dependent chemotaxis assay with 3 cell
lines harboring detectable levels of CXCR4 (Additional
file 1: Figure S3) and in a set of seven CLL primary sam-
ples, either untreated or pre-treated with IQS019 or with
the standard CXCR4 antagonist AMD3100. The migra-
tion induced by recombinant CXCL12 in MCL, FL and
DLBCL cell lines was significantly inhibited by the
compound at all the doses tested (Fig. 4a). The statistical
significance of this effect was higher at the 2.5 μM than
at the 1 μM dose in DOHH-2 and OCI-LY10 cells, while
an almost complete inhibition of cell migration was
achieved in UPN-1 cells at the lowest dose. In the case
of CLL primary cells, since the stimulation of BCR has
been shown to facilitate CXCL12-mediated migration
[15], we evaluated the activity of IQS019 after BCR
crosslinking. As shown in Fig. 4b, c, IQS019 significantly
overcame IgM-activated, CXCL12-dependent chemotaxis
in all the primary samples tested, either at the 1 μM dose
(mean inhibition: 51.5%; range: 23.9–85.5%; p = 0.0013)
or at the 2.5 μM dose (mean inhibition: 82.9%; range:
63.4–97.6%; p < 0.0001), when compared to untreated
control cells. Accordingly, the mean fraction of cells
with detectable F-actin polymerization shifted from
13.8% in control cells to 75.1% after CXCL12 stimula-
tion, and was lowered down to 25.9% in the presence of
IQS019 (Fig. 4d, *** p = 0.0003). Of special interest, when
comparing with AMD3100, IQS019 showed similar, or
even superior anti-migratory activity (Fig. 4a, b and c).
These results indicate that IQS019-mediated inhibition
of BCR upstream kinases may interfere with B cell
chemotaxis and tumor cell dissemination.
IQS019 is safe and impairs tumor outgrowth and
malignant B cell homing to spleen in vivo
In order to validate the activity of IQS019 in vivo, we
first synthesized the salt form of the compound, there-
after labeled as IQS019-2MeSO3H, and evaluated its
Fig. 2 IQS019 impairs constitutive phosphorylation of Syk, Lyn and Btk tyrosine kinases in malignant B cells. a UPN-1, DOHH-2, OCI-LY10, and
JVM-13 cells (6 x 106) were treated with increasing concentrations of IQS019 for 6 h, followed by Western Blot detection of phospho(p)-Syk, and
p-Lyn, using β- actin as a loading control. Shown is a representative experiment from two replicates. b Flow cytometry analysis of p-Btk levels in
cell lines treated as before. A PE-labeled mouse IgG1 κ was used as an isotype control (grey filled histogram). Indicated are the relative median
fluorescence intensity (r) values observed after treatment with 5 μM IQS019 (grey curves), and referred to control untreated cells (black curves)
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single-dose toxicity over 14 days after intravenous ad-
ministration in healthy immunodeficient (SCID) mice
(details in Additional file 1 Methods). As the maximum
tolerated dose was not reached, 2 and 10 mg/kg doses
were selected for further in vivo experiments. We then
developed two different, complementary xenotransplant
animal models of the two entities showing increased
sensitivity to the compound in vitro, i.e., MCL and FL.
Heterotopic MCL tumors were generated in SCID mice
subcutaneously inoculated with UPN-1 cells, while a
systemic (i.e., characterized by homing of tumor B cells
from peripheral blood to spleen) FL tumor model was
obtained by intravenous injection of DOHH-2 cells in
SCID mice. As shown in Fig. 5a, after two weeks of
treatment, mice bearing MCL tumors and dosed with
IQS019-2MeSO3H showed a 63% reduction in tumor
volume, when compared to the vehicle group (*p < 0.05).
There was not subsequent improvement of the anti-
tumor activity of the compound between the 2 mg/kg
and the 10 mg/kg dosing, suggesting that optimal
Fig. 3 IQS019 overcomes anti-Ig-mediated BCR activation in B lymphoid cell lines and primary samples. Representative cell lines and primary
cultures were pre-treated for 1.5 h with increasing concentrations of IQS019, followed by anti-Ig-mediated BCR ligation, as described in
methods section. a Expression levels of p-Syk and p-Lyn were analyzed by Western Blot, as previously, using β-actin as a loading control.
Shown is a representative experiment from two replicates. b p-Btk levels were analyzed as previously by flow cytometry in B lymphoid cell
lines and primary cultures, pre-stimulated with their respective anti-Ig and either untreated (black curves) or exposed to 5 μM IQS019 (grey curves ).
Shown is a representative experiment from a CLL patient out of a series of six cases
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activity was reached at the lowest dose. Consistently,
tumor metabolism was similarly decreased in both treat-
ment groups, as glucose uptake fell to 50–52% in tumors
from all IQS019-2MeSO3H-exposed animals, irrespect-
ive of the dose (Fig. 5b). This effect was closely related
to the inhibition of the three BCR-related kinases Syk,
Lyn, and Btk, as shown by a complete reduction of their
phosphorylated forms in the drug-treated specimens,
when compared to the control group (Fig. 5c). Immuno-
histochemical analysis of representative tumor sections
further revealed that IQS019 therapy efficiently reduced
the mitotic index and induced apoptosis in UPN-1-
derived tumors, as shown by a decreased labeling of
phospho-histone H3 and an intracellular increase in the
activated form of caspase-3 (Fig. 5c).
In the systemic DOHH-2 mouse model, mice dosing
was initiated at day 7 post-inoculation, with a 2 mg/kg
IQS019-2MeSO3H regimen, daily, for 15 days. Once in-
oculated, FL cells rapidly migrate to the spleen [16].
Therefore, at the end of the procedure, entire spleens
were processed, and the presence of malignant B cells
was evaluated by labeling with anti-human CD45 anti-
body and tumor cell recounting on a flow cytometer.
IQS019-2MeSO3H treatment induced a 52% reduction
in tumor cell infiltration into the spleen, when com-
pared to vehicle group (Fig. 5d, * p = 0.01). Accordingly,
the r fluorescence values of phospho-Syk, phospho-Btk,
and phospho-Lyn, decreased by 83, 57, and 33% in tu-
mors B cells purified from IQS019-treated animals
(Fig. 5e). Altogether, these results demonstrate that
IQS019 is safe and exhibits in vivo efficacy against
MCL and FL tumor burden, involving the inhibition of
BCR signaling and the blockade of tumor cell homing
to lymphoid compartment.
Fig. 4 IQS019 interferes with malignant B cell chemotaxis. Representative, CXCR4-expressing B lymphoid cell lines (a) and a set of n = 7 CLL
primary samples (b) were exposed for 1.5 h to 1 or 2.5 μM IQS019, with or without Ig-mediated BCR stimulation, followed by cytofluorimetric
recounting of cells migrated towards recombinant CXCL12 in a 4-h transwell assay. Treatment with the CXCR4 antagonist AMD3100 (40 μM)
was used as a control of chemotaxis blockade. Expressed are the ratios between CXCL12-dependent and CXCL12-unspecific migration. c Cell
migration profiles from two representative CLL cases are shown. d A set of six CLL cultures were treated as above with CXCL12 +/- IQS019 and
stained with phalloidin-TRITC. Cells with high levels of polymerized F-actin were recounted for each condition by two independent reviewers.
Shown are the mean results obtained from the six cases. Statistical significance: * p < 0.05, ** p < 0.01, *** p < 0.001
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IQS019 shows superior anti-tumor activity than ibrutinib
in vitro and in vivo
We previously reported that IQS019 presented an in-
creased anti-proliferative activity in vitro when com-
pared to ibrutinib, in a single MCL cell line and at a
single time point [13]. To confirm this preliminary
experiment, we compared by MTT assay the anti-
proliferative effect of IQS019 and ibrutinib at 24, 48,
and 72 h, using doses ranging from 0.5 to 10 μM, in a
panel of eight cell lines that included the ibrutinib-
sensitive MINO, REC-1, UPN-1, DOHH-2, and WSU-
NHL and the ibrutinib-resistant Z-138, GRANTA-519,
and JVM-2 cells. Figure 6a shows that the mean IC50 of
ibrutinib remained significantly high (i.e., > 10 μM) in
this set of cell lines, even after a 72-h drug exposure,
mainly due to the high values observed in the resistant
cell lines (152.4 μM for Z-138, 22.1 μM for GRANTA-
519 and 77.4 μM for JVM-2). In contrast, IQS09-
mediated proliferation blockade was almost completely
reached in all the cell lines after only 24 hours, with a
Fig. 5 IQS019 impairs tumor growth and homing of B lymphoid cells to spleen in vivo. a SCID mice were inoculated with UPN-1 cells and began
treatment at day 10 post-inoculation with 2 or 10 mg/kg IQS019-2MeSO3H or equal volume of vehicle. IQS019-2MeSO3H was administrated 5 days
a week for 2 weeks. b Lower panel, intratumoral glucose uptake was evaluated in representative mice injected intravenously with an IR800-labeled
2-deoxy glucose probe 24 h prior sacrifice, and visualized with an Odyssey infra-red scanner (Li-Cor). Upper panel, relative fluorescence quantification
by means of the Image Studio software shows markedly reduced glucose uptake in tumor masses from mice receiving IQS019-2MeSO3H,
when compared to vehicle-treated animals. c Immunostaining of consecutive sections from representative UPN-1-derived tumors, showing
the decrease of proliferation and the induction of apoptosis accompanying the downregulation of p-Syk, p-Lyn and p-Btk upon IQS019-2MeSO3H
treatment (magnification 200X). d Mice were injected intravenously with DOHH-2 cells and, after one week, received a 2 mg/kg dose of
IQS019-2MeSO3H or vehicle, daily, for up to 14 days. Mice were then sacrificed and human (CD45+) malignant B cells were recounted from
spleen as described in methods section (statistical significance: * p < 0.05). e In each treatment group, CD45+/CD20+ human B cells isolated
from n = 3 representative animals, were labeled with anti-p-Syk, anti-p-Lyn, or anti-p-Btk antibody, and fluorescence was recorded on a cytometer.
Shown are the relative r values among control and vehicle group, calculated for each phospho-kinase
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mean IC50 of 6.7 μM (range: 2.7–8.7 μM), which de-
creased down to 4.1 μM (range: 2.2–11.7 μM) and
3.3 μM (range: 2.2-5.1 μM) at 48 h and 72 h, respect-
ively. Of particular interest, after 72 h these IC50 values
were much lower in Z-138 (4.5 μM), GRANTA-519
(5.1 μM), and JVM-2 cells (4.1 μM) than observed after
ibrutinib treatment. Accordingly, while a short expos-
ure to ibrutinib only marginally affected CXCL12-
dependent cell migration in the UPN-1 cell line, this
process was blocked up to 39% in cells cultured with
IQS019 (Fig. 6b). To validate these observations in in
vivo settings, MCL tumor-bearing mice were treated
with a standard 25 mg/kg dose of ibrutinib [17], the
equivalent dose of IQS019-2MeSO3H, or vehicle. While
ibrutinib allowed to a significant 25.1% reduction in
tumor growth after 2 weeks of treatment (* p = 0.049),
IQS019-2MeSO3H showed superior activity, as it could
inhibit the tumor outgrowth up to 42% when compared
to vehicle group (Fig. 6c, ** p = 0.006, * p = 0.048). At
the pharmacokinetic level, while both compounds
Fig. 6 Improved in vitro and in vivo activity of IQS019 vs the Btk inhibitor ibrutinib. a A panel of eight B-NHL cell lines was incubated with increasing
concentrations of IQS019 or ibrutinib for 24, 48, and 72 h and IC50 was calculated as previously. b IQS019 has improved anti-migratory activity. UPN-1
cells were exposed to 5 μM IQS019 or ibrutinib for 90 min followed by evaluation of CXCL12-dependent cell chemotaxis, as described in methods
section. Statistical significance: ** p < 0.01. c Orally administered IQS019 impairs tumor outgrowth more efficiently than ibrutinib. SCID mice were
inoculated with UPN-1 cells subcutaneously and, at day 10 post-inoculation, started to be dosed p.o., 5 days a week, for two weeks, with 25 mg/kg
IQS019-2MeSO3H, 25 mg/kg ibrutinib or equal volume of vehicle (n = 10 animals per group). Tumor volumes were recorded as above. Statistical
significance: * p < 0.05, ** p < 0.01. d Western blot analysis of phospho-Lyk, phospho-Syk and (e) cytofluorimetric analysis of phospho-Btk in UPN-1
and UPN-IbruR cells treated for 6 h with indicated doses of IQS019 or ibrutinib. For phospho-Btk analysis, cells were exposed to a single dose of
each agent (5 μM) 90 min prior to IgM stimulation and cell labeling. Indicated are the r values observed after treatment with IQS019 (grey curves)
or ibrutinib (red curves), and referred to control IgM-stimulated cells (black curves). Isotype controls are represented by grey filled histograms.
Shown are representative experiments from two replicates
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presented similar half-life and Cmax values in mice after
a single oral administration, the total drug exposure
over time was considerably improved in the case of
IQS019-2MeSO3H, as shown by a 12 fold increase in
the AUC value. Consequently, the global bioavailability
dropped from 2 to 4% in the case of ibrutinib, to about
70% in the case of IQS019-2MeSO3H (Additional file 1:
Figure S4b and Table S3), thus suggesting that a better
PK profile may account for the improved activity of
IQS019 vs ibrutinib in vivo.
To unravel at the molecular level the mechanisms
underlying this superior activity of IQS019 over the Btk
inhibitor, we established an ibrutinib-resistant cell line
designated UPN-IbruR, derived from the parental UPN-
1 by repeated drug selection (Additional file 1 Methods).
When compared with the parental cell line, UPN-IbruR
presented approximately a 10-fold increase in the ibruti-
nib IC50 after 72 h of treatment (24.6 vs 2.4 μM for
parental cells), with negligible difference in IQS019 IC50
(5.6 vs 2.3 μM for parental cells) (Additional file 1:
Figure S5a).The ibrutinib resistance phenotype of UPN-
IbruR cells was not associated to mutations in BTK or
PLCG2 genes, which both harbored a wild type sequence
(Additional file 1: Figure S5b), but may rather be
associated to the activation of non-canonical NF-κB
pathway, as suggested by the overexpression of p52
(Additional file 1: Figure S5c). While a similar dose-
dependent decrease in phospho-Lyn and phospho-Btk
levels was found in IQS019- and in ibrutinib-treated
UPN-1 cells, the expression of phospho-Syk was almost
completely lost only in cells exposed to 1 μM IQS019
(Fig. 6d,e). In sharp contrast, in UPN-IbruR cells, the
Btk inhibitor failed to modulate the phosphorylation of
the three kinases, while IQS019 showed significant in-
hibitory activity of phospho-Syk and phospho-Lyn at a
dose as low as 1 μM (Fig. 6d). However, the compound
was unable to downregulate phospho-Btk (Fig. 6e), sug-
gesting that in ibrutinib-resistant cells, the capacity of
IQS019 to inhibit Syk and Lyn may allow the com-
pound to maintain a significant antitumoral activity in-
dependent of the expression of a non-druggable form
of Btk. Altogether, these results point out a significant
superior antitumoral activity of pleiotropic BCR kinase
targeting by IQS019 over the sole inhibition of Btk, in
in vitro and in vivo models of B-NHL.
Discussion
BCR has recently emerged as a central oncogenic pathway
that promotes growth and survival in various lymphoma
subtypes [8]. Constitutive activation of the three BCR-
related kinases Syk, Lyn, and Btk have been well docu-
mented in CLL [18–20], MCL [21, 22], and FL [23] cells,
while chronic BCR signaling has been reported in the
ABC subtype of DLBCL [5]. Consistently, BCR kinase
inhibitors constitute promising therapeutic strategies in
these different entities. Among these novel agents, the
first-in-class Btk inhibitor ibrutinib has achieved high re-
sponse rates (43–71%) in relapsed/refractory CLL, MCL
and ABC-DLBCL patients, while its activity was less
pronounced in FL patients (37% overall response rate)
[24–27]. A small fraction of patients develop progressive
disease after initial response to this agent [25, 27], in rela-
tion with the acquisition of mutations at the ibrutinib
binding site (C481S) of Btk, or in the PLCγ2 gene [9–11].
Resistance to ibrutinib may also involve a lower depend-
ency of malignant B cells toward Btk itself, than other
downstream components of the pathway, like the Syk/
Lyn-dependent kinase Erk [28]. Accordingly, the Syk in-
hibitor fostamatinib and the Src inhibitor dasatinib have
also shown efficacy in relapsed/refractory B-NHL [29, 30].
Following these observations, and in an effort to im-
prove the therapeutic modulation of BCR signaling, we
previously screened a library of compounds derived from
pyrido[2,3-d]pyrimidines, for their capacity to bind to
the active sites of Btk, Syk and/or Lyn [31]. We identi-
fied IQS019 (compound 19) as a unique molecule with
affinity for the three BCR kinases [13]. In the present
work, we confirm the inhibitory property of the com-
pound against Btk, Syk and Lyn, as well as its selective
antitumoral effect in B lymphoid cells, especially in
MCL and FL cell lines, and independently of the re-
sponse to ibrutinib. Our results suggest that IQS019 can
counteract both chronic and tonic BCR signaling, as it
shows similar antiproliferative activity in DLBCL cell
lines from both the GCB and ABC subtype, which are
respectively dependent for their survival on tonic (Syk/
PI3K-mediated) and chronic (Syk/Btk-mediated) BCR
signaling [8, 32–34]. This property might confer to
IQS019 a greater activity than ibrutinib, which is prefer-
entially active against tumors that rely on chronic active
BCR signaling [8]. Beside Btk, the direct inhibitory activity
of IQS019 towards Syk and/or Lyn phosphorylation may
also explain the capacity of the compound to activate
apoptosis in vitro and in vivo, as pharmacological inhib-
ition of Syk, has been reported to elicit the apoptotic cas-
cade in preclinical models of DLBCL and CLL [35, 36].
Also, probably thanks to its apoptogenic property and spe-
cificity, IQS019 salt is found to be significantly active and
safe at a dose of 2 mg/kg/day, which is much lower than
the reported active concentrations of fostamatinib, dasati-
nib or ibrutinib in mouse models of lymphoid neoplasms
[37–39], thus predicting a probable low incidence of sec-
ondary adverse effects of the compound.
Another downstream event regulated by Btk, Syk, and
Lyn is the chemokine-mediated B cell migration, a
process essential to tumor B cell survival [40]. We show
that IQS019 is able to impair in vitro cell migration
towards CXCL12 in cell lines and primary samples, in
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both basal and anti-Ig-stimulated cultures. This property
may be responsible, at least in part, for the reduced infil-
tration of tumor cell observed in FL-bearing mice dosed
with the compound. Beside this effect, IQS019-mediated
inhibition of Syk, Lyn, and Btk may further impair tumor
maintenance and B cell homeostasis in vivo, which are
largely dependent on the coordinated activity of the three
kinases [41].
Conclusions
In summary, we describe IQS019 as a new and unique BCR
kinase inhibitor able to counteract both constitutive and
ligand-dependent activation of the BCR pathway in in vitro
and in vivo models of B lymphoid neoplasms. Thanks to
the unique capacity of the compound to inhibit the three
upstream BCR kinases Lyn, Syk, and Btk, this study may
offer a glimpse into possible application for the treatment
of the most prevalent subtypes of B-NHL, including
those low responders to current BCR kinase inhibitors.
Additional file
Additional file 1: Figure S1. IQS019 tyrosine kinase inhibitory profiling.
Tyrosine kinase (TK) and tyrosine kinase-like (TKL) kinome tree was elabo-
rated on the basis of residual in vitro kinase activity upon exposure to
100 nM or 1 μM IQS019, by means of Kinome Render software (http://
bcb.med.usherbrooke.ca/kinomerender.php). Figure S2. Sensitivity of CLL
primary cases to IQS019 is independent of IGHV mutational status and in-
volves a caspase-dependent cell death process. (a) CLL primary cells, 9 of
them with ummutated (UM) and 6 with mutated (M) IGHV gene, were
treated with increasing concentrations of IQS019 for 24h. Cell viability
was determined by MTT method. Shown are the median values from
each CLL group (UM and M), referred to control, untreated cells. (b)
IQS019 induces caspase-dependent cell death in MCL (UPN-1) and in FL
(DOHH-2) cell lines, as well as in two representative CLL primary cultures.
Cells were exposed for 24 hours to 5 μM IQS019, in the presence of ab-
sence of the pan-caspase inhibitor Q-VD-OPh (10 μM). Apoptosis was de-
termined by simultaneous cytofluorimetric detection of Annexin-V and
caspase-3/7 activity. (c) A set of 6 CLL primary cultures were treated with
IQS019 as indicated, followed by Western Blot detection of phospho-
histone H3 (p-H3), using β- actin as a loading control. Figure S3. Flow cy-
tometry determination of CXCR4 membrane expression in B-NHL cell
lines. Four representative cell lines were stained with a PE-labeled anti-
CXCR4 antibody and analyzed on an Attune cytometer. CXCR4-specific
signal (black curves) and isotypic control (grey filled curve) are repre-
sented. Figure S4. Safety and PK properties of IQS019-2MeSO3H in mice.
(a) Twenty SCID mice (10 males and 10 females) received a single intra-
venous injection of IQS019-2MeSO3H at a 2 mg/kg, 10 mg/kg, or 50 mg/
kg dose, or equivalent volume of vehicle, and animal weight was re-
corded at days 1, 3, 4, 7, 11, 14, 18 and 21 post-treatment. (b) Mean
plasma concentration of IQS019-2MeSO3H in ICR mice over the time,
after a single p.o. administration of a 25 mg/kg dose of the compound.
Figure S5. Comparison of parental and ibrutinib-resistant derived B-NHL
cell line. (a) Dose-response of the UPN-1 parental, and UPN-IbruR derived
cell line exposed for 72 hours to increasing concentrations of ibrutinib or
IQS019. (b) BTK and PLCG2 exon sequencing in UPN-IbruR cells. (c) West-
ern blot detection of the alternative NF-κB pathway component, p52, in
UPN-1 and UPN-IbruR cells. β-actin was used as a loading control. (DOC
3279 kb)
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